Post-Polycythemia Vera Myelofibrosis Market – Pipeline Review, H2 2017

“The Latest Research Report Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. –”

About Post-Polycythemia Vera Myelofibrosis Market

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Pipeline Review, H2 2017, provides an overview of the Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) pipeline landscape.

Post-Polycythemia Vera Myelofibrosis (PPV-MF) is a myeloproliferative blood cancer in which the bone marrow makes too many red blood cells. It may also result in the overproduction of white blood cells and platelets. Symptoms include heart attack, stroke, deep venous thrombosis, Headaches, lack of concentration and fatigue. The disease may be controlled by chemotherapy, transfusions, transplant and medications.

Get Sample copy of this Report @

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 12, 5 and 1 respectively.

Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

View Sample PDF @


– The pipeline guide provides a snapshot of the global therapeutic landscape of Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology).

– The pipeline guide reviews pipeline therapeutics for Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology)

Reasons to buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

– Find and recognize significant and varied types of therapeutics under development for Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology).

– Classify potential new clients or partners in the target demographic.

– Develop tactical initiatives by understanding the focus areas of leading companies.

– Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.

– Formulate corrective measures for pipeline projects by understanding Post-Polycythemia Vera Myelofibrosis (PPV-MF) (Oncology) pipeline depth and focus of Indication therapeutics.

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Send An Enquiry Request @

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Overview 6

Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Products under Development by Companies 10

Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Therapeutics Assessment 11

Assessment by Target 11

Assessment by Mechanism of Action 13

Assessment by Route of Administration 15

Assessment by Molecule Type 17

Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Companies Involved in Therapeutics Development 19

AbbVie Inc 19

Celgene Corp 19

CTI BioPharma Corp 20

F. Hoffmann-La Roche Ltd 20

Gilead Sciences Inc 21

Incyte Corp 21

Italfarmaco SpA 22

JW Pharmaceutical Corp 22

MedImmune LLC 23

MEI Pharma Inc 23

Merck & Co Inc 24

Novartis AG 24

NS Pharma Inc 25

Promedior Inc 25

Sun Pharma Advanced Research Company Ltd 26

Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Drug Profiles 27

buparlisib hydrochloride-Drug Profile 27

CWP-291-Drug Profile 33

durvalumab-Drug Profile 35

givinostat-Drug Profile 54

glasdegib-Drug Profile 57

idelalisib-Drug Profile 60

IMG-7289-Drug Profile 68

INCB-50465-Drug Profile 70

itacitinib adipate-Drug Profile 72

LCL-161-Drug Profile 76

navitoclax dihydrochloride-Drug Profile 77

NS-018-Drug Profile 80

pacritinib-Drug Profile 82

pembrolizumab-Drug Profile 96

pomalidomide-Drug Profile 164

pracinostat-Drug Profile 171

PRM-151-Drug Profile 178

sonidegib phosphate-Drug Profile 183

vismodegib-Drug Profile 188

Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Dormant Projects 194

Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Discontinued Products 195

Post-Polycythemia Vera Myelofibrosis (PPV-MF)-Product Development Milestones 196

Featured News & Press Releases 196

Appendix 197

Methodology 197

Coverage 197

Secondary Research 197

Primary Research 197

Expert Panel Validation 197

Contact Us 197

Disclaimer 198

About us is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.


Mr. Nachiket

State Tower

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-621-2074



Designed by
Powered by
%d bloggers like this: